Taro announced the launch of Keveyis (dichlorphenamide) tablets, the first therapy approved for the treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants. Keveyis was approved by the Food and Drug Administration (FDA) in August 2015.
The approval of Keveyis, a carbonic anhydrase inhibitor, was based on data from two multicenter, double-blind, placebo-controlled studies. The precise mechanism by which dichlorphenamide exerts its therapeutic effects in patients with periodic paralysis is unknown.
Keveyis is supplied in 50mg strength tablets in 100-count bottles. It is available through its specialty pharmacy partner, Diplomat.
For more information call (866) 923-4914 or visit Keveyis.com.